Fig. 2: Effects of EBV serostatus on clinical responses to teplizumab.
From: Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
A Kaplan Meier curve showing the progression from Stage 2 T1D to Stage 3 T1D in TN10 study participants who were EBV-seropositive (n = 18, teplizumab (blue), n = 16 placebo (green)) or EBV-seronegative (n = 26 teplizumab (yellow), 16 placebo (magenta)) at enrollment. Median times to development of Stage 3 T1D: Placebo EBV-seronegative: 12 months; Placebo EBV-seropositive: 35.5 months; Teplizumab EBV-seronegative: 38 months; Teplizumab EBV-seropositive: 86.9 months (Logrank p = 0.005) (See text for subgroup comparisons). B In the AbATE trial (control: n = 16 EBV-seronegative (magenta), n = 7 EBV-seropositive (green), treatment: n = 34 EBV-seronegative (yellow), n = 18 EBV-seropositive (blue)). The data are the least square means of the lnC-peptide(AUC + 1) ( ± 95%CI), corrected for the baseline level and age, from the mixed model. (Control EBV-seronegative vs teplizumab EBV-seronegative (group difference of least square means (LSM, (95% CI): 0.111 (.063, 0.159) p < 0.0001), Control EBV-seropositive vs teplizumab EBV-seropositive (0.19(0.122, 0.258), p < 0.0001). Teplizumab EBV-seronegative vs teplizumab EBV-seropositive (0.066 (0.016, 0.11) **p = 0.008). The annotated comparisons are between teplizumab treated participants who were EBV-seropositive vs EBV-seronegative. Source data are provided in the Source Data file.
